

Table 19.25
Non-Hodgkin LymphomaEstimated United States Cancer Prevalence Counts^a on January 1, 2012
By Race/Ethnicity, Sex and Years Since Diagnosis

Years Since Diagnosis		0 to <5	5 to <10	10 to <15	15 to <20	20 to <25	25 to <30	0 to <20 ^e	0 to <37 ^e	>=37 ^g	Complete ^h
<u>Race</u>	<u>Sex</u>										
All Races ^b	Both Sexes	205,597	143,043	87,628	50,507	28,179	15,884	499,961	541,393	8,232	549,625
	Males	110,512	73,527	45,359	26,351	14,922	8,603	262,705	284,672	4,332	289,004
	Females	95,085	69,516	42,269	24,156	13,257	7,281	237,256	256,721	3,900	260,621
White ^b	Both Sexes	177,024	125,584	77,296	44,460	25,369	14,430	436,199	473,815	8,597	482,412
	Males	95,569	64,896	40,143	23,215	13,477	7,779	230,047	250,031	4,868	254,899
	Females	81,455	60,688	37,153	21,245	11,892	6,651	206,152	223,784	3,729	227,513
Black ^b	Both Sexes	16,520	11,569	6,486	3,710	1,796	916	39,149	41,616	683	42,299
	Males	8,420	5,675	3,240	1,899	923	534	19,661	20,969	289	21,258
	Females	8,100	5,894	3,246	1,811	873	382	19,488	20,647	394	21,041
Asian/ Pacific Islander ^c	Both Sexes	6,342	3,800	2,382	+	+	+	13,826	+	+	+
	Males	3,369	1,919	1,274	+	+	+	7,211	+	+	+
	Females	2,973	1,881	1,108	+	+	+	6,615	+	+	+
Hispanic ^d	Both Sexes	16,134	9,712	5,785	+	+	+	34,651	+	+	+
	Males	8,441	4,947	3,073	+	+	+	18,053	+	+	+
	Females	7,693	4,765	2,712	+	+	+	16,598	+	+	+

Estimated prevalence percent^a on January 1, 2012, of the SEER^c population diagnosed in the previous 20 years
By Age at Prevalence, Race/Ethnicity and Sex

Age at Prevalence		Age Specific (Crude)									Age-Adjusted ^f	
		All Ages	0-9	10-19	20-29	30-39	40-49	50-59	60-69	70-79	80+	All Ages
<u>Race</u>	<u>Sex</u>											
All Races ^c	Both Sexes	0.1402%	0.0029%	0.0120%	0.0252%	0.0461%	0.0991%	0.1958%	0.3710%	0.5961%	0.6826%	0.1347%
	Males	0.1498%	0.0037%	0.0159%	0.0306%	0.0540%	0.1166%	0.2266%	0.4203%	0.6685%	0.7803%	0.1546%
	Females	0.1309%	0.0021%	0.0078%	0.0196%	0.0382%	0.0818%	0.1664%	0.3265%	0.5375%	0.6248%	0.1173%
White ^c	Both Sexes	0.1571%	0.0030%	0.0125%	0.0264%	0.0479%	0.1057%	0.2098%	0.3998%	0.6519%	0.7289%	0.1446%
	Males	0.1671%	0.0039%	0.0170%	0.0322%	0.0560%	0.1248%	0.2425%	0.4471%	0.7281%	0.8267%	0.1653%
	Females	0.1472%	0.0021%	0.0077%	0.0202%	0.0393%	0.0860%	0.1774%	0.3557%	0.5885%	0.6705%	0.1260%
Black ^c	Both Sexes	0.0878%	0.0026%	0.0110%	0.0244%	0.0509%	0.0921%	0.1623%	0.2844%	0.3672%	0.3532%	0.0996%
	Males	0.0934%	0.0027%	0.0130%	0.0312%	0.0621%	0.1046%	0.1884%	0.3394%	0.3521%	0.4004%	0.1117%
	Females	0.0828%	0.0025%	0.0090%	0.0178%	0.0411%	0.0811%	0.1395%	0.2413%	0.3778%	0.3302%	0.0896%
Asian/ Pacific Islander ^c	Both Sexes	0.0883%	0.0029%	0.0102%	0.0189%	0.0305%	0.0618%	0.1243%	0.2260%	0.3764%	0.4951%	0.0876%
	Males	0.0955%	0.0035%	0.0134%	0.0209%	0.0343%	0.0693%	0.1429%	0.2605%	0.4486%	0.5988%	0.1027%
	Females	0.0818%	0.0023%	0.0067%	0.0169%	0.0270%	0.0552%	0.1084%	0.1974%	0.3206%	0.4317%	0.0758%
Hispanic ^d	Both Sexes	0.0679%	0.0031%	0.0094%	0.0196%	0.0324%	0.0771%	0.1502%	0.2847%	0.4602%	0.5289%	0.1042%
	Males	0.0695%	0.0036%	0.0126%	0.0231%	0.0384%	0.0875%	0.1692%	0.2984%	0.4720%	0.5701%	0.1130%
	Females	0.0663%	0.0026%	0.0061%	0.0157%	0.0260%	0.0662%	0.1319%	0.2730%	0.4515%	0.5043%	0.0962%

^a US 2012 cancer prevalence counts are based on 2012 cancer prevalence proportions from the SEER registries and 1/1/2012 US population estimates based on the average of 2011 and 2012 population estimates from the US Bureau of the Census. Prevalence was calculated using the First Malignant Primary Only for a person.

^{b c d} Statistics based on (b) SEER 9 Areas (c) SEER 11 Areas and Rural Georgia (d) NHIA for Hispanic for SEER 11 Areas and Rural Georgia.

^e Maximum limited-duration prevalence: 37 years for 1975-2012 SEER 9 data; 20 years for 1992-2012 SEER 11 data (used to calculate prevalence for Hispanics and Asian Pacific Islanders).

^f Percentages are age-adjusted to the 2000 US Standard Population (19 age groups - Census P25-1130) by 5-year age groups.

^{g h i} (g) Cases diagnosed more than 37 years ago were estimated using the completeness index method (Capocaccia et. al. 1997, Merrill et. al. 2000). (h) Complete prevalence is obtained by summing 0 to <37 and >=37. (i) Age-specific completeness index was approximated using empirical data from historical Connecticut tumor registry.

- Statistic not shown. Statistic based on fewer than 5 cases estimated alive in SEER for the time interval.

+ Not available.